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In In the following sentence, the reference has been changed to 25 rather than 22:
Thirdly, it remains unclear in which treatment line everolimus should be used. So far, data from RADIANT-3 trial [25] did not show any differences in efficacy depending on previous use of chemotherapy, compared to the use of everolimus in therapy-naive patients.
The below reference has been corrected: 27. Pavel ME, Hainsworth JD, Baudin E et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005 Lancet 378: -2012 
